Results 111 to 120 of about 7,681 (214)

Efficacy of tiotropium–olodaterol fixed-dose combination in COPD

International Journal of COPD, 2016
Eric Derom, Guy G Brusselle, Guy F Joos Department of Respiratory Medicine, Ghent University Hospital, Ghent, BelgiumAbstract: Tiotropium–olodaterol, formulated in the Respimat soft-mist inhaler, is an inhaled fixed-dose combination (FDC) of a long-
Derom E, Brusselle GG, Joos GF
doaj  

Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD

, 2008
A-B Tonnel1, T Perez1, J-M Grosbois2, C Verkindre2, M-L Bravo3, M Brun3 on behalf of the TIPHON study groupa1Centre Hospitalier Régional Universitaire (CHRU) de Lille, Lille Cedex, France; 2Centre Hospitalier de Béthune, B& ...
M-L Bravo, J-M Grosbois, A-B Tonnel, C Verkindre, et al, T Perez   +5 more
core  

Tiotropium - Advancing the treatment of COPD

, 2008
Inhaled anticholinergic bronchodilators are a treatment of choice for chronic obstructive pulmonary disease (COPD). Tiotropium is currently the only long-acting inhaled anticholinergic bronchodilator available and works by selectively inhibiting ...
Tallia, AF, Stevens, R, Rasmussen, J, Gaw, A, Barakat, K, Dalrymple, J, Elward, K, Halpin, D, Schachter, M, North, F, LeFevre, M, Tamargo, J, Spann, S, Waller, D, Morrell, J, Uden, D, Kassianos, G, Kirby, M, Waite, M, Ganiats, T, Yawn, R, Price, D, Brown, P, Chambers, S, Yawn, B   +24 more
core  

Superiority of tiotropium plus olodaterol in comparison with salmeterol plus fluticasone

, 2016
Tomohiro Tamura, Hiroaki Satoh Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Ibaraki, Japan We read with interest the article entitled “The lung function profile of once-daily tiotropium and olodaterol via ...
Satoh H, Tamura T
core  

Safety analysis of long-acting dual bronchodilator after market approval: a real-world study from FDA Adverse Event Reporting System (FAERS) database. [PDF]

J Thorac Dis
Gao S, Zhuang W, Song Q, Yan D, Chen L, Lai Z, Cheng Y, Yang X, Hu S.   +8 more
europepmc   +1 more source

Identifying patients with mild-to-moderate COPD who require intensified initial treatment to control annualized clinically important deterioration. [PDF]

NPJ Prim Care Respir Med
Wang Z, Zhou Y, Guan WJ, Lin J, Cai G, Zheng J, Wu F, Deng Z, Zhong NS, Ran P.   +9 more
europepmc   +1 more source

Effect of inhaled anticholinergics on bronchial secretions: a systematic review. [PDF]

Front Physiol
Arzayus-Patiño L, Bernal-Sanchez JJ, Pérez-Hortua V, Wilches-Luna EC, Benavides-Cordoba V.   +4 more
europepmc   +1 more source

Early impact of treatment with tiotropium, long-acting anticholinergic preparation, in patients with COPD – real-life experience from an observational study

, 2015
Karina Jahnz-Różyk,1 Pawel Szepiel2 1Department of Immunology and Clinical Allergology, Military Institute of Medicine, Warsaw, Poland; 2Boehringer Ingelheim Sp.
Jahnz-Różyk K, Szepiel P
core  

Determination of Particle Size of Active Pharmaceutical Ingredients in Dry Powder Inhaler Formulations. [PDF]

Pharmaceuticals (Basel)
Fertaki S, Orkoula M, Kontoyannis C.
europepmc   +1 more source

Tiotropium in Patients With Airflow Limitation According to the Fixed Ratio But Not the Lower Limit of Normal: A Secondary Analysis of the Tiotropium in Early-COPD Study. [PDF]

Chronic Obstr Pulm Dis
Zhou K, Wu F, Deng Z, Wan Q, Huang S, Zhong N, Zhou Y, Ran P.   +7 more
europepmc   +1 more source